QBIOTICS REPORTS 80% OBJECTIVE RESPONSE RATE IN INJECTED TUMOURS IN STAGE 1 OF PHASE IIA CLINICAL TRIAL OF TIGILANOL TIGLATE FOR SOFT TISSUE SARCOMA
- Written by PR Newswire Asia - News Pronto RSS
 |
BRISBANE, Australia, June 25, 2025 /PRNewswire/ --
.
PR Newswire
More Articles ...
- BANNER S C (TULLIMBAR) PTY LTD ANNOUNCES OFFERING OF AUD 5,649,878 SENIOR SECURED LOAN NOTE OFFER
- UOB Asset Management anticipates a greater focus on Asian markets in 3Q 2025
- Trinasolar and Universidad Politécnica de Madrid Strengthen Partnership with Inauguration of Demo Center
- CMC Invest Embarks on Strategic Transformation of Post-Trade Operations in Partnership with Contemi NOVA
- E-Invoicing Could Unlock Over A$22 Billion for the Australian Economy, Avalara Finds